GlassScriptPhysician profile
Reginald I Obi
NPI 1841224490
$3,690.26
in general payments reported to CMS, 2019-2025
25 companies · $2,057 in 2025
The $2,057 reported for 2025 was more than what 89% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $482 · 2020: $221 · 2021: $187 · 2022: $259 · 2023: $348 · 2024: $137 · 2025: $2,057.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,317 · Food and Beverage: $1,216 · Education: $8.19.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,316.60 |
| Food and Beverage | $1,216.36 |
| Education | $8.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $1,973.37 | 2025 | |
| Vifor Pharma, INC. | $413.91 | 2019-2023 | Veltassa |
| Alexion Pharmaceuticals, INC. | $248.89 | 2019-2023 | Ultomiris |
| Amgen INC. | $137.05 | 2019-2024 | Tavneos |
| Aurinia Pharma U.S., INC. | $124.26 | 2021-2023 | Lupkynis |
| Mallinckrodt Hospital Products INC. | $106.97 | 2020-2023 | Acthar |
| Bayer Healthcare Pharmaceuticals INC. | $95.15 | 2022-2024 | |
| Otsuka America Pharmaceutical, INC. | $77.63 | 2019-2023 | Jynarque |
| Calliditas Therapeutics US INC. | $56.30 | 2022 | |
| Glaxosmithkline, LLC. | $53.26 | 2023-2024 | Benlysta, Jesduvroq |
| Mallinckrodt Enterprises LLC | $45.99 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $42.54 | 2019-2022 | |
| Opko Pharmaceuticals, LLC | $40.93 | 2019 | |
| Allergan, INC. | $37.45 | 2019-2020 | |
| Genzyme Corporation | $36.04 | 2019-2023 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Recor Medical INC | $34.81 | 2025 | Paradise Ultrasound Renal Denervation System |
| Travere Therapeutics, INC. | $30.96 | 2024-2025 | Filspari |
| Stryker Corporation | $29.57 | 2025 | Flowtriever |
| Akebia Therapeutics INC | $21.67 | 2020 | |
| Fresenius USA Marketing, INC. | $19.10 | 2021 | |
| La Jolla Pharmaceutical Company | $18.31 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.61 | 2025 | Xifaxan |
| Shire North American Group INC | $16.65 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.84 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reginald Obi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.